Neoepitope detection of disease using protein arrays
A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays.
1. A biosensor for use in detecting the presence of ovarian cancer, said biosensor comprising an immunoassay for detecting a presence of a serum antibody reactive with at least one marker antigen indicative of ovarian cancer, said at least one marker antigen being incorporated into said immunoassay, said at least one marker antigen being selected from the group consisting of
polypeptides comprising SEQ ID NOS: 153, 154, 155, 156, 157, 158, 161, 162, 163, 164, 165, 166, 167, 168, 171, 172, 173, 174, 176, 177, 178, 179, 180, 183, 184, and 186, each of said polypeptides being either an isolated polypeptide or an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone;
polypeptides consisting of SEQ ID NOS: 160, 175, and 181, each of said polypeptides being either an isolated polypeptide or an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone; and
polypeptides consisting of SEQ ID NOS: 159, 169, 170, 182, and 185, each of said polypeptides being an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone.
2. The biosensor according to claim 1 , wherein said immunoassay is selected from the group consisting of a microarray immunoassay, a macroarray immunoassay, a slide immunoassay, and a filter containing specific marker antigens.
3. A diagnostic tool for determining the efficacy of a pharmaceutical for treating ovarian cancer, said tool comprising:
an immunoassay for detecting a presence of a serum antibody reactive with at least one marker antigen indicative of ovarian cancer, said at least one marker antigen being incorporated into said immunoassay, and
analyzing means operatively connected to said immunoassay, said analyzing means for determining fluctuations in amount of said serum antibody reactive with said at least one marker antigen present in said immunoassay, whereby said fluctuations correlate to pharmaceutical efficacy,
said at least one marker antigen being selected from the group consisting of
polypeptides comprising SEQ ID NOS: 153, 154, 155, 156, 157, 158, 161, 162, 163, 164, 165, 166, 167, 168, 171, 172, 173, 174, 176, 177, 178, 179, 180, 183, 184, and 186, each of said polypeptides being either an isolated polypeptide or an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone;
polypeptides consisting of SEQ ID NOS: 160, 175, and 181, each of said polypeptides being either an isolated polypeptide or an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone; and
polypeptides consisting of SEQ ID NOS: 159, 169, 170, 182, and 185, each of said polypeptides being an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone.
4. An antigen array for use in detecting the presence of ovarian cancer, said array consisting of a set of polypeptides, said set of polypeptides consisting of
polypeptides comprising SEQ ID NOS: 153, 154, 155, 156, 157, 158, 161, 162, 163, 164, 165, 166, 167, 168, 171, 172, 173, 174, 176, 177, 178, 179, 180, 183, 184, and 186, each of said polypeptides being either an isolated polypeptide or an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone;
polypeptides consisting of SEQ ID NOS: 160, 175, and 181, each of said polypeptides being either an isolated polypeptide or an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone; and
polypeptides consisting of SEQ ID NOS: 159, 169, 170, 182, and 185, each of said polypeptides being an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone.
5. The array according to claim 4 , wherein said array is selected from the group consisting of a microarray, spinning disk, antigens bound to colored beads, and a macroarray.
6. Markers for detecting the presence of ovarian cancer selected from the group consisting of polypeptides comprising SEQ ID NOS: 153, 154, 155, 156, 157, 158, 161, 162, 163, 164, 165, 166, 167, 168, 171, 172, 173, 174, 176, 177, 178, 179, 180, 183, 184, and 186, each of said polypeptides being either an isolated polypeptide or an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone;
polypeptides consisting of SEQ ID NOS: 160, 175, and 181, each of said polypeptides being either an isolated polypeptide or an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone; and
polypeptides consisting of SEQ ID NOS: 159, 169, 170, 182, and 185, each of said polypeptides being an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone.
7. An immuno-imaging agent comprising labeled antibodies, whereby said labeled antibodies are selected by reaction with at least one marker antigen selected from the group consisting of polypeptides comprising SEQ ID NOS: SEQ ID NOS: 153, 154, 155, 156, 157, 158, 161, 162, 163, 164, 165, 166, 167, 168, 169, 171, 172, 173, 174, 176, 177, 178, 179, 180, 183, 184, 185, and 186, each of said polypeptides being either an isolated polypeptide or an insert in frame with the T7 10B gene product in an isolated T7 phage display antigen clone.
8. The agent according to claim 7 , wherein said at least one marker antigen is identified by the biosensor of claim 1 .